Smac/DIABLO release from mitochondria and XIAP inhibition are essential to limit clonogenicity of Type I tumor cells after TRAIL receptor stimulation
Chiel Maas(The Netherlands Cancer Institute), Jannie Borst(Leiden University Medical Center)
Cited by 42
Related Papers
A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex
|The Journal of Immunology|1991|128
Ubiquitination by the Membrane-associated RING-CH-8 (MARCH-8) Ligase Controls Steady-state Cell Surface Expression of Tumor Necrosis Factor-related Apoptosis Inducing Ligand (TRAIL) Receptor 1*
|Journal of Biological Chemistry|2013|85
Radiotherapy and Cisplatin Increase Immunotherapy Efficacy by Enabling Local and Systemic Intratumoral T-cell Activity
|Cancer Immunology Research|2019|46
IFN-Stimulated Gene 15 Is an Alarmin that Boosts the CTL Response via an Innate, NK Cell–Dependent Route
|The Journal of Immunology|2020|37
Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95/Fas via c-FLIP downregulation
|Cell Death and Differentiation|2009|24